RxDoctor Payments Data

Andrew Bierman

Family · Carlsbad, CANPI 1306408505

Payments from drug & device makers

$12,805in general payments, 2019–2025

Across 417 payments — averaging $30.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$4K
  • AbbVie$3K
  • Novartis$901
  • TG Therapeutics, Inc.$735
  • Amgen$705
  • AstraZeneca$350
  • plus $3K from 17 others

What the payments were for

  • Consulting fees$4,20033%
  • Travel & lodging$6125%
  • Food & beverage$7,89362%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,805 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$10,555
Medicare patients
84
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate103$612,720
Glatiramer Acetate71$188,206
Kesimpta PenOfatumumab11$91,958
GlatopaGlatiramer Acetate15$50,240
Dalfampridine ErDalfampridine38$18,973
UbrelvyUbrogepant12$16,840
GemtesaVibegron11$12,508
Baclofen103$4,996
Modafinil40$3,493
Gabapentin86$1,955
Levetiracetam30$1,242
Tizanidine Hcl33$950
Oxcarbazepine12$706
Duloxetine Hcl27$688
Divalproex Sodium ErDivalproex Sodium27$679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$231$612,720103 claims
AbbVieUbrelvy$2,753$16,84012 claims
Upsher-smith Laboratories LLCTopiramate$333$13412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.

Other family in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →